Pancreatic ductal adenocarcinoma (PDAC) comprises approximately 90% of pancreatic cancer cases, with the majority of those patients carrying active KRAS mutations [4, 5]. The gene discussed is KRAS; the disease is pancreatic ductal adenocarcinoma.